Revolution Medicines (RVMD) Interest & Investment Income (2019 - 2026)

Revolution Medicines' Interest & Investment Income history runs 8 years deep, the most recent figure standing at $19.5 million for Q1 2026.

• On a quarterly basis, Interest & Investment Income fell 21.7% year-over-year to $19.5 million in Q1 2026; TTM through Mar 2026 was $130.1 million, a 154.32% increase from a year earlier, with the FY2025 full-year figure at $90.7 million, up 4.39% from the prior year.
• Interest & Investment Income retreated to $19.5 million in Q1 2026 per RVMD's latest filing, from $88.9 million in the prior quarter.
• Across five years, Interest & Investment Income topped out at $88.9 million in Q4 2025 and bottomed at -$1.8 million in Q4 2022.
• The 5-year median for Interest & Investment Income is $1.2 million (2023), against an average of $10.7 million.
• Across the five-year window, Interest & Investment Income sank 1613.21% in 2022 and jumped 1530.25% in 2025, its largest moves.
• Year by year, Interest & Investment Income stood at -$1.8 million in 2022, then jumped by 180.72% to $1.4 million in 2023, then soared by 1400.0% to $21.2 million in 2024, then jumped by 318.84% to $88.9 million in 2025, then sank by 78.06% to $19.5 million in 2026.
• Per Business Quant, the three latest RVMD Interest & Investment Income figures stand at $19.5 million (Q1 2026), $88.9 million (Q4 2025), and $22.1 million (Q3 2025).